Genome editing of a
Disclosed herein are methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a DNA binding domain and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
1. An isolated fusion protein comprising a Fokl nuclease domain and one or more TAL effector (TALE) polypeptides comprising a plurality of TALE repeat domains, wherein each TALE repeat domain comprises a RVD, wherein:
(i) each RVD of said TALE repeat domains bind to a target site in a Rosa gene, wherein said target site is selected from the group consisting of the nucleotide sequence of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, and SEQ ID NO: 90: and further wherein said RVD comprises the amino acids NI, HI, Al, CI, DI, El, RI or KI which recognizes adenine (A) in said target site; the amino acids HD, AD, KD, YD, ED, AD, ND or RD which recognizes cytosine (C) in said target site; the amino acids NN, DK, DH, KN, EN, AN, CN, GN, FN, AK, NK or CK which recognizes guanine (G) in said target site; and the amino acids NG, KG MG, QG, RG, AA, QA, IG, IP, LA, YG, HG, SG, VG, IA or VA which recognizes thymine (T) in said target site; and
(ii) said fusion protein cleaves said Rosa gene.
2. The isolated fusion protein of claim 1 , wherein said Fokl nuclease domain is naturally occurring or engineered.
3. A polynucleotide encoding said isolated fusion protein of claim 1 .
4. An isolated cell comprising said isolated fusion protein of claim 1 , wherein said isolated cell is not a human embryonic cell.
5. An isolated cell comprising the polynucleotide of claim 3 , wherein said isolated cell is not a human embryonic cell.
6. The isolated cell of claim 4 , wherein said isolated cell is a rat or mouse embryonic cell.
7. A composition comprising said isolated fusion protein of claim 1 and a pharmaceutically acceptable excipient.
8. A composition comprising said polynucleotide of claim 3 and a pharmaceutically acceptable excipient.
9. A method for cleaving one or more Rosa genes in an isolated rat or mouse cell, said method comprising:
introducing into said isolated rat or mouse cell, one or more isolated fusion proteins of claim 1 into said isolated rat or mouse cell, such that the one or more Rosa gene are cleaved.
10. The method of claim 9 , wherein said one or more fusion proteins are introduced by transforming said isolated rat or mouse cell with polynucleotides encoding said isolated fusion proteins.
11. A method of introducing an exogenous polynucleotide sequence into the genome of an isolated rat or mouse cell, said method comprising:
cleaving one or more Rosa genes by the method of claim 9 ; and
contacting said isolated rat or mouse cell with an exogenous polynucleotide sequence;
wherein cleavage of said one or more Rosa genes stimulates integration of said exogenous polynucleotide sequence into the genome of said isolated cell by homologous recombination.
12. The method of claim 11 , wherein said exogenous polynucleotide sequence is integrated into the genome via nucleic acid replication processes.
13. The method of claim 11 , wherein said exogenous polynucleotide sequence is integrated into the genome via non-homology dependent targeted integration.
14. A method of modifying a Rosa gene sequence in the genome of an isolated rat or mouse cell, said method comprising:
cleaving one or more Rosa genes by the method of claim 9 , wherein said cleavage results in a modification of said Rosa gene sequence by non-homologous end joining or homology directed repair.
15. The method of claim 14 , wherein said modification comprises a deletion.
16. The method of claim 14 , wherein said modification comprises insertion of an exogenous sequence.
17. A kit comprising the isolated fusion protein of claim 1 .
18. A kit comprising the polynucleotide of claim 3 .
19. The kit of claim 17 , further comprising additional components selected from the group consisting of one or more exogenous sequences, instructions for use, and combinations thereof.
20. The kit of claim 18 , further comprising additional components selected from the group consisting of one or more exogenous sequences, instructions for use, and combinations thereof.